DDInter1696 DDInter1376
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Solifenacin {u} (Compound) resembles {v} (Compound) Mequitazine
Solifenacin {u} (Compound) resembles {v} (Compound) Benazepril
Solifenacin {u} (Compound) binds {v} (Gene) CHRM4
Solifenacin {u} (Compound) palliates {v} (Disease) multiple sclerosis
Solifenacin {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Muscarinic Antagonists
Solifenacin {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Solifenacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Solifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Solifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Solifenacin {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Solifenacin (Compound) resembles Mequitazine (Compound)
Solifenacin (Compound) resembles Benazepril (Compound)
Solifenacin (Compound) binds CHRM4 (Gene)
Solifenacin (Compound) palliates multiple sclerosis (Disease)
Solifenacin (Compound) is included by Cholinergic Muscarinic Antagonists (Pharmacologic Class)
Solifenacin (Compound) causes Atrial fibrillation (Side Effect)
Solifenacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone
Solifenacin may lead to a major life threatening interaction when taken with Potassium chloride